Monoclonal antibody therapy in Langerhans cell histiocytosis--feasible and reasonable?
Many recent studies have demonstrated the range of disorders in which monoclonal antibodies have a clinical role. The monoclonal antibody NA1/34, directed against a surface antigen present on lesional cells ('LCH cells'), has been found to localise in vivo to sites of disease. This review explores the possible applications and limitations of monoclonal antibody based-therapy in Langerhans cell histiocytosis.
Kelly
K M
KM
Division of Hematology/Oncology, Children's Hospital of Philadelphia, PA 19104.
Pritchard
J
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000954:Antigens, Surface / Q000276:immunology; D005544:Forecasting; D006646:Histiocytosis, Langerhans-Cell / Q000276:immunology / Q000628:therapy*; D006801:Humans
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface